Back to today’s briefing

Story perspectives

Study Reveals MS Treatments Impact Stroke Risk Significantly

5/30/2025

32 3

Summary

Story summary

A recent European study reveals that disease-modifying therapies (DMTs) for multiple sclerosis (MS) significantly lower stroke risk, especially glatiramer acetate and dimethyl fumarate. However, fingolimod may heighten this risk. This research underscores the importance of tailoring DMT choices to safeguard cardiovascular health in MS patients, as detailed in Therapeutic Advances in Neurological Disorders.

1 of 1

Story summary

A recent European study reveals that disease-modifying therapies (DMTs) for multiple sclerosis (MS) significantly lower stroke risk, especially glatiramer acetate and dimethyl fumarate. However, fingolimod may heighten this risk. This research underscores the importance of tailoring DMT choices to safeguard cardiovascular health in MS patients, as detailed in Therapeutic Advances in Neurological Disorders.